An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma

NCT07469683 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

78

Enrollment

OTHER

Sponsor class

Conditions

Clear Cell Renal Cell Carcinoma
Neoplasms
Malignant Neoplasms
Malignant Neoplasm of Kidney, Except Renal Pelvis

Interventions

DRUG: SLC-3010 + Axitinib
DRUG: Axitinib

Sponsor

Yonsei University